Related Experiment Video

Updated: Jun 24, 2025

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.2K

The biological roles of CD47 in ovarian cancer progression

Linan Xing1, Zhao Wang2, Yue Feng2

  • 1Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.

Cancer Immunology, Immunotherapy : CII
|June 4, 2024
PubMed

Insights

Ovarian cancer frequently relapses after treatment. Targeting the CD47 immune checkpoint shows promise for new immunotherapies, offering hope for patients with this lethal cancer.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Ovarian cancer is a highly lethal malignancy with a poor prognosis.
  • High relapse rates (65-80%) occur after initial treatment, with no effective therapies established.
  • The CD47/Sirpα immune checkpoint is a critical target in cancer immunotherapy.

Purpose of the Study:

  • To review the biological roles of CD47 in ovarian cancer.
  • To summarize the mechanisms of CD47 in ovarian cancer progression and immune evasion.
  • To highlight CD47 as a potential immunotherapy target for ovarian cancer.

Main Methods:

  • Literature review of studies on CD47 in ovarian cancer.
  • Analysis of CD47/Sirpα pathway in cancer immune evasion.
  • Synthesis of current research on CD47-targeted therapies.

Main Results:

  • CD47 plays significant roles in ovarian cancer biology and immune evasion.
  • The CD47/Sirpα axis is a key immune checkpoint in various cancers.
  • CD47 monoclonal antibodies and related agents show therapeutic potential.

Conclusions:

  • CD47 is a promising target for ovarian cancer immunotherapy.
  • Further research into CD47-targeting agents is warranted.
  • Future clinical applications may include novel immunotherapy regimens for ovarian cancer.
Keywords:
CD47ImmunotherapyOvarian cancerSirpαTSP-1

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.7K
Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity09:00

Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity

Published on: December 31, 2015

26.6K

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K